Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. META
5. ACN
6. NVDA
7. IBM
8. PRIM
9. SPY
10. PFE

Go back to Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

Biogen (BIIB) PT Lowered to $260 at RBC Capital

October 31, 2024 6:31 AM EDT

RBC Capital analyst Brian Abrahams lowered the price target on Biogen (NASDAQ: BIIB) to $260.00 (from $269.00) while maintaining a Outperform rating.

The analyst comments "3Q showed BIIB remains a company in transition, with some bright spots like ex-U.S. Leqembi, improving operating... More

Biogen (BIIB) PT Raised to $315 at Piper Sandler

October 30, 2024 4:54 PM EDT

Piper Sandler analyst Christopher Raymond raised the price target on Biogen (NASDAQ: BIIB) to $315.00 (from $307.00) while maintaining a Overweight rating.

The analyst comments "Remain OW rated on BIIB shares after a solid Q324 beat/FY24 guidance raise. While some may quibble... More

Goldman Sachs Reiterates Buy Rating on Biogen (BIIB)

October 30, 2024 4:37 PM EDT

Goldman Sachs analyst Salveen Richter reiterated a Buy rating and $290.00 price target on Biogen (NASDAQ: BIIB).

The analyst comments "BIIB posted in-line 3Q revenue, inclusive of Leqembi's beat and Skyclarys' miss, and higher EPS per cost-savings. Leqembi's launch remains affected by infrastructure/logistical challenges, where we continue to expect a gradual, albeit progressing, uptake curve and are... More